Posted by admin on Jul 23rd, 2022

Stryker (NYSE:SYK – Get Rating) and G Medical Innovations (NASDAQ:GMVD – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

This is a breakdown of recent ratings and recommmendations for Stryker and G Medical Innovations, as provided by MarketBeat.

Stryker currently has a consensus target price of $270.53, indicating a potential upside of 35.66%. Given Stryker’s higher possible upside, equities research analysts plainly believe Stryker is more favorable than G Medical Innovations.

This table compares Stryker and G Medical Innovations’ gross revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than G Medical Innovations.

74.5% of Stryker shares are owned by institutional investors. 6.7% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

This table compares Stryker and G Medical Innovations’ net margins, return on equity and return on assets.

Stryker beats G Medical Innovations on 8 of the 8 factors compared between the two stocks.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Rotork plc (LON:ROR) Given Average Recommendation of “Moderate Buy” by Brokerages

Associated Banc (NYSE:ASB) Trading Up 5.3% on Better-Than-Expected Earnings